Tarbox Family Office’s IGM Biosciences IGMS Stock Holding History

Tarbox Family Office’s Portfolio IGMS Stock Details IGMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-22	Closed	-$1K	–	1101
2021 Q4	$1K	Buy	+22	New	+$1.09K	﹤0.01%	1010

Other funds holding IGMS

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Tarbox Family Office's IGMS Position: Q1 2022 in Review

Tarbox Family Office sold out of IGM Biosciences (IGMS) in Q1 2022, closing a stake of 22 shares — an estimated $1K sold.

Tarbox Family Office first reported a position in IGMS in Q4 2021 and held it in 1 quarter. The position peaked at $1K in Q4 2021. 93 funds tracked by Wall St. Rank hold IGMS as of Q1 2022.

Tarbox Family Office reported no remaining IGM Biosciences position as of Q1 2022 after selling out during the quarter.
Tarbox Family Office sold 22 IGM Biosciences shares in Q1 2022, an estimated $1K.
Tarbox Family Office first reported a position in IGM Biosciences in Q4 2021 and held it in 1 quarter.
Tarbox Family Office's IGM Biosciences position peaked at $1K in Q4 2021.
93 funds tracked by Wall St. Rank held IGM Biosciences as of Q1 2022.

Based on Tarbox Family Office's 13F filing for Q1 2022, filed 25 Apr 2022.